N | 12 |
Demographics | |
Median age (range) | 55.5 (30–78) |
Male | 8 (75%) |
White | 12 (100%) |
Medicare or private insurance | 12 (100%) |
Previous opioid used | |
Heroin | 2 (17%) |
Prescribed opioids | 9 (75%) |
Illicit prescription opioids | 3 (25%) |
Illicit buprenorphine | 3 (25%) |
Concurrent substance use | |
Tobacco | 4 (33%) |
Cocaine | 5 (42%) |
Marijuana | 3 (25%) |
Retention | |
30-day | 9 (75%) |
90-day | 8 (67%) |
End of study | 7 (58%) |
Referral source | |
Attending | 3 (25%) |
Resident | 9 (75%) |
Dosing characteristics | |
Median induction dose (range) | 16 mg (2–16) |
Median maintenance dose (range) | 24 mg (8–24) |